Skip to main content
Premium Trial:

Request an Annual Quote

DiaDexus Funds Michigan s Hanash in Biomarker Research Deal

NEW YORK, Sept. 4-DiaDexus will support University of Michigan geneticist Samir Hanash in research using proteomic techniques to develop new biomarkers to diagnose and treat cancer, the company said today.

DiaDexus will provide research funding in exchange for exclusive licensing rights to discoveries of commercial interest. The University of Michigan also stands to receive milestone and royalty payments on any products developed out of the collaboration.


Hanash's research will focus on identifying cell surface membrane proteins as potential therapeutic targets or biomarkers. His team will analyze normal and cancerous biological samples and cell lines with a sensitive technique.


DiaDexus did not disclose the financial terms of the arrangement.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.